Literature DB >> 30199502

A Polymer-Based Extended Release System for Stable, Long-term Intracochlear Drug Delivery.

Erik Pierstorff1, Shanshan Chen2, Maria Paola Chaparro3, John M Cortez2, Yen-Jung Chen3, Su Young Ryu4, Sherry M Tsai4, Marc M Baum4, Wan Wan Yang1, Federico Kalinec5, Thomas Smith1, Stacey Ludwig2, William H Slattery1.   

Abstract

OBJECTIVE: Investigate a new polymer-based drug coating suitability for safe intracochlear delivery and ability to maintain long-term physiologically active levels of the corticosteroid fluticasone propionate. STUDY
DESIGN: In vitro dissolution study to evaluate release profiles of polymer-coated drug particles and in vivo studies using a guinea pig model to measure perilymph drug concentrations at specific time points after implantation with polymer-coated drug particles and evaluate their effect on hearing function.
METHODS: Polymer-coated fluticasone propionate (FP) particles were surgically implanted in guinea pigs through the round window membrane into the cochlear scala tympani. In the pilot study, pre- and post-op hearing thresholds were conducted on days 7, 14, and 42. In a second study, post-op hearing thresholds were conducted on days 90, 120, and 180. Perilymph drug concentrations were measured on the same time points.
RESULTS: In 15 of 16 animals from day 7 through day 90, drug levels were within the targeted range, with no initial burst release detected. Drug was present in all animals on day 90 and was detected in some animals at 120 and 180 days. Hearing was tested and compared with non-implanted ears. Very good hearing preservation was observed in ears implanted with intracochlear particles when compared with contralateral ears.
CONCLUSIONS: The polymer-based extended release system is effective in providing long-term, stable drug delivery for at least 90 days with good hearing outcomes. The results of this study support the potential for achieving long-term drug delivery with a single intracochlear administration.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30199502      PMCID: PMC6132259          DOI: 10.1097/MAO.0000000000001977

Source DB:  PubMed          Journal:  Otol Neurotol        ISSN: 1531-7129            Impact factor:   2.311


  27 in total

1.  OTO-104: a sustained-release dexamethasone hydrogel for the treatment of otic disorders.

Authors:  Fabrice Piu; Xiaobo Wang; Rayne Fernandez; Luis Dellamary; Anne Harrop; Qiang Ye; Jenifer Sweet; Rachel Tapp; David F Dolan; Richard A Altschuler; Jay Lichter; Carl LeBel
Journal:  Otol Neurotol       Date:  2011-01       Impact factor: 2.311

2.  Quantitative interpretation of corticosteroid pharmacokinetics in inner fluids using computer simulations.

Authors:  Stefan K R Plontke; Alec N Salt
Journal:  Hear Res       Date:  2003-08       Impact factor: 3.208

3.  Dose-dependent sustained release of dexamethasone in inner ear cochlear fluids using a novel local delivery approach.

Authors:  Xiaobo Wang; Luis Dellamary; Rayne Fernandez; Anne Harrop; Elizabeth M Keithley; Jeffrey P Harris; Qiang Ye; Jay Lichter; Carl LeBel; Fabrice Piu
Journal:  Audiol Neurootol       Date:  2009-11-16       Impact factor: 1.854

4.  Age-related alterations in the auditory brainstem responses and the compound action potentials in guinea pigs.

Authors:  I Nozawa; S Imamura; I Fujimori; K Hashimoto; S Shimomura; K Hisamatsu; Y Murakami
Journal:  Laryngoscope       Date:  1996-08       Impact factor: 3.325

5.  Pharmacokinetic and pharmacodynamic evaluation of fluticasone propionate after inhaled administration.

Authors:  H Möllmann; M Wagner; B Meibohm; G Hochhaus; J Barth; R Stöckmann; M Krieg; H Weisser; C Falcoz; H Derendorf
Journal:  Eur J Clin Pharmacol       Date:  1998-02       Impact factor: 2.953

6.  Presence of type I and type II/IB receptors for adrenocorticosteroid hormones in the inner ear.

Authors:  K E Rarey; W G Luttge
Journal:  Hear Res       Date:  1989-09       Impact factor: 3.208

7.  Aldosterone and prednisolone control of cochlear function in MRL/MpJ-Fas(lpr) autoimmune mice.

Authors:  D R Trune; J B Kempton
Journal:  Hear Res       Date:  2001-05       Impact factor: 3.208

8.  Glucocorticoid-stimulated, transcription-independent release of annexin A1 by cochlear Hensen cells.

Authors:  F Kalinec; P Webster; A Maricle; D Guerrero; D N Chakravarti; B Chakravarti; R Gellibolian; G Kalinec
Journal:  Br J Pharmacol       Date:  2009-12       Impact factor: 8.739

9.  Dexamethasone levels and base-to-apex concentration gradients in the scala tympani perilymph after intracochlear delivery in the guinea pig.

Authors:  Hartmut Hahn; Alec N Salt; Thorsten Biegner; Bernd Kammerer; Ursular Delabar; Jared J Hartsock; Stefan K Plontke
Journal:  Otol Neurotol       Date:  2012-06       Impact factor: 2.311

10.  Magnetic targeted delivery of dexamethasone acetate across the round window membrane in guinea pigs.

Authors:  Xiaoping Du; Kejian Chen; Satish Kuriyavar; Richard D Kopke; Brian P Grady; David H Bourne; Wei Li; Kenneth J Dormer
Journal:  Otol Neurotol       Date:  2013-01       Impact factor: 2.311

View more
  4 in total

1.  Prevention of cisplatin-induced hearing loss by extended release fluticasone propionate intracochlear implants.

Authors:  Erik Pierstorff; Wan-Wan Yang; Yen-Jung Angel Chen; Shirley Cheung; Federico Kalinec; William H Slattery
Journal:  Int J Pediatr Otorhinolaryngol       Date:  2019-03-20       Impact factor: 1.675

Review 2.  Inner ear delivery: Challenges and opportunities.

Authors:  Betsy Szeto; Harry Chiang; Chris Valentini; Michelle Yu; Jeffrey W Kysar; Anil K Lalwani
Journal:  Laryngoscope Investig Otolaryngol       Date:  2019-12-11

3.  Safety and audiological outcome in a case series of tertiary therapy of sudden hearing loss with a biodegradable drug delivery implant for controlled release of dexamethasone to the inner ear.

Authors:  Stefan K Plontke; Arne Liebau; Eric Lehner; Daniel Bethmann; Karsten Mäder; Torsten Rahne
Journal:  Front Neurosci       Date:  2022-09-20       Impact factor: 5.152

4.  Microimaging of a novel intracochlear drug delivery device in combination with cochlear implants in the human inner ear.

Authors:  Eric Lehner; Matthias Menzel; Daniel Gündel; Stefan K Plontke; Karsten Mäder; Jessica Klehm; Heike Kielstein; Arne Liebau
Journal:  Drug Deliv Transl Res       Date:  2021-02-04       Impact factor: 4.617

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.